Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics)

Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics) was approved to establish in June 2011 by Tianjin Science and Technology Commission and Tianjin Education Commission. Based on the School of Pharmacy of Tianjin Medical University, the key laboratory establishes a teaching and research cooperation mechanism that closely connects the school with the affiliated hospitals, aiming to solve the key technical problems of clinical drugs in the treatment of major diseases, and promote the transfer of basic research technologies into clinical applications. The past and current chairmen of the laboratory academic committee are Prof. Xishan Hao (Academician of the Chinese Academy of Engineering) and Prof. Jingkang Wang (Academician of the Chinese Academy of Engineering). The vice chairmen of the laboratory academic committee are Prof. Zhirong Zhang from Sichuan University and Prof. Qiang Zhang from Peking University. The first director of the laboratory was Prof. Victor Yang, a tenured professor at the University of Michigan. The current director of the laboratory is Prof. Xiongwen Chen, Dean of School of Pharmacy, Tianjin Medical University. The vice directors of the laboratory are Prof. Yangping Liu and Prof. Huining He, both of whom are vice deans of School of Pharmacy.

The research interests of the key laboratory not only focus on the oncology pharmacy and cardiovascular pharmacy, but also lie in solving the common key problems of drug R & D and their clinical applications. From the foundation of the key laboratory to the end of the year 2021, the lab has 147 funded projects include 77 national-level longitudinal scientific research projects, 39 provincial-level longitudinal scientific research projects and 46 horizontal scientific research projects. The total research funding exceeds 61.72 million RMB. The laboratory has published more than 573 scientific papers, of which 496 are SCI indexed; 3 provincial and ministerial-level science and technology awards have been obtained, and 70 patents have been granted.

The laboratory adheres to the principle of resource sharing and openness to the outside world. A total of 15 open projects have been funded. The laboratory has always attached great importance to exchanges and cooperation with domestic and foreign universities and scientific research institutions. At present, it has established good international partnerships with scientific research institutions in many countries and regions such as the United States, Japan, South Korea and South Africa. Since its establishment, the laboratory continuously aims at integrating the Tianjin medical resources, establishing the “Great Tianjin Pharmaceutical Alliance” and becoming an indispensable platform for the integration of medical science and drugs and transformation of achievements, actively promoting developments of Tianjin bio-medical science and industries.Uptill now, the laboratory has established cooperation with large pharmaceutical companies in Tianjin, including Tianjin Pharmaceuticals Group, Tianjin Institute of Pharmaceutical Research, Tasly Holding Group, and Tianjin Chase Sun Pharmaceutical Co., Ltd ect.